Proton beam boost: new hope for inoperable sarcomas?
NCT ID NCT07173972
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers to predict who responds best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton radiotherapy
- What this could lead to
- If successful, this could offer a more effective radiation option for patients with inoperable soft tissue sarcoma, potentially improving tumor control without increasing side effects.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 40 participants, so results may not apply to all patients. The higher radiation dose could also cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA (LMS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haukeland University Hospital
NOT_YET_RECRUITINGBergen, Norway
-
Oslo University Hospital
RECRUITINGOslo, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Experimental combo aims to tackle Treatment-Resistant cancers
- Can tailored exercise help young sarcoma survivors recover strength?
- Blood test may spot hidden sarcoma signals